Monalizumab

Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid tumors 1-year survival data of monalizumab in combination with cetuximab in h ead and neck...

Monalizumab is a first-in-class broad-spectrum immune checkpoint inhibitor with a dual effect on both Natural Killer (NK) cells and T lymphocytes Monalizumab showed promising preclinical and clinical...

These data support the advancement of the clinical program, starting with the enrollment of an additional cohort of patients who received both prior platinum-based chemotherapy and PD-1/L1 inhibitors...

Innate Pharma acquires US and EU rights to commercialize Lumoxiti to become a fully-integrated oncology-focused biotech AstraZeneca obtains full oncology rights to monalizumab AstraZeneca gains access...

Confirmation of previously reported response rate and new data on durability of response reinforces the potential anti-tumor activity of the monalizumab cetuximab combination Clinical program advances...

Management to host KOL call on updated data from the ongoing Phase II trial of monalizumab and cetuximab on Monday, October 22, 4pm CEST (10 am EDT) Innate Pharma SA (the “Company” - Euronext Paris...

Updated clinical data show preliminary anti-tumor activity in patients with recurrent/metastatic microsatellite -stable colorectal cancer (MSS-CRC ), a population historically unresponsive to PD-1/L1...

Preliminary activity observed in patients with recurrent/metastatic microsatellite -stable colorectal cancer (MSS-CRC ), a population historically unresponsive to PD-1/L1 blockade 3 partial responses...